according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 18.06.2025 4893032-00022 Date of first issue: 17.09.2019 6.1

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name Pyrantel Pamoate / Ivermectin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-: Veterinary product

stance/Mixture

Recommended restrictions Not applicable

on use

1.3 Details of the supplier of the safety data sheet

**MSD** Company Kilsheelan

Clonmel Tipperary, IE

Telephone 353-51-601000

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

## 1.4 Emergency telephone number

+1-908-423-6000

#### **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

## Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - single ex-

posure, Category 2

H371: May cause damage to organs.

H373: May cause damage to organs through pro-

Specific target organ toxicity - repeated

longed or repeated exposure.

exposure, Category 2

Short-term (acute) aquatic hazard, Cate-

H400: Very toxic to aquatic life.

Long-term (chronic) aquatic hazard, Cat-

H410: Very toxic to aquatic life with long lasting

egory 1

effects.

### 2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Pyrantel Pamoate / Ivermectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

Hazard pictograms :





Signal word : Warning

Hazard statements : H371 May cause damage to organs.

H373 May cause damage to organs through prolonged or

repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

Response:

P308 + P311 IF exposed or concerned: Call a POISON

CENTER/ doctor. P391 Collect spillage.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

**Ivermectin** 

#### **Additional Labelling**

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 38,3 %

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

#### Components

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

Chemical name  4,4'-methylenebis[3-hydroxy-2- naphthoic] acid, compound with (E)- 1,4,5,6-tetrahydro-1-methyl-2-[2-(2- thienyl)vinyl]pyrimidine (1:1)	CAS-No. EC-No. Index-No. Registration number 22204-24-6 244-837-1	Classification	Concentration (% w/w) >= 30 - < 50
Ivermectin	70288-86-7 274-536-0	Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 ——— M-Factor (Acute aquatic toxicity): 10.000 M-Factor (Chronic aquatic toxicity): 10.000	>= 1 - < 2,5
Ethanol#	64-17-5 200-578-6 603-002-00-5	Flam. Liq. 2; H225 Eye Irrit. 2; H319 ————————————————————————————————————	>= 0,1 - < 1

For explanation of abbreviations see section 16.

#: Voluntarily-disclosed substance

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 6.1 18.06.2025 4893032-00022 Date of first issue: 17.09.2019

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do

so by medical personnel. Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause damage to organs.

May cause damage to organs through prolonged or repeated

exposure.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

### **SECTION 5: Firefighting measures**

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

Carbon oxides

Nitrogen oxides (NOx)

Sulphur oxides

#### 5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

#### **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Avoid breathing vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

sessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

## 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
4,4'- methylenebis[3- hydroxy-2- naphthoic] acid, compound with (E)-1,4,5,6- tetrahydro-1- methyl-2-[2-(2- thienyl)vinyl]pyrimi dine (1:1)	22204-24-6	TWA	250 μg/m3 (OEB 2)	Internal
Propylene glycol	57-55-6	TWA	25 ppm 79 mg/m3	FOR-2011- 12-06-1358
Ivermectin	70288-86-7	TWA	30 μg/m3 (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	300 μg/100 cm2	Internal
Ethanol	64-17-5	TWA	500 ppm	FOR-2011-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

6.1	18.06.2025	4893032-00022	Date of first issue: 17.09.2019	
Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025	

950 mg/m3 12-06-1358

## Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects Value	
Glycerine	Workers	Inhalation	Long-term local ef- fects 56 mg/m3	
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local ef- fects	33 mg/m3
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
Ethanol	Workers	Inhalation	Long-term systemic effects	380 mg/m3
	Workers	Skin contact	Long-term systemic effects	267 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	114 mg/m3

## Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Ivermectin	Fresh water	0,000004 mg/l
	Marine water	0,000004 mg/l
Glycerine	Fresh water	0,885 mg/l
	Marine water	0,0885 mg/l
	Intermittent use/release	8,85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3,3 mg/kg dry
		weight (d.w.)
	Marine sediment	0,33 mg/kg dry
		weight (d.w.)
	Soil	0,141 mg/kg dry
		weight (d.w.)
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry
		weight (d.w.)
	Marine sediment	57,2 mg/kg dry
		weight (d.w.)
	Soil	50 mg/kg dry
		weight (d.w.)
Ethanol	Fresh water	0,96 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 18.06.2025 4893032-00022 Date of first issue: 17.09.2019 6.1

Freshwater - intermittent	2,75 mg/l
Marine water	0,79 mg/l
Sewage treatment plant	580 mg/l
Fresh water sediment	3,6 mg/kg dry weight (d.w.)
Marine sediment	2,9 mg/kg dry weight (d.w.)
Soil	0,63 mg/kg dry weight (d.w.)
Oral (Secondary Poisoning)	380 mg/kg food

### 8.2 Exposure controls

### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

Eye/face protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material Chemical-resistant gloves

Remarks Consider double gloving.

Skin and body protection Work uniform or laboratory coat.

> Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter should conform to NS EN 14387

Filter type Combined particulates and organic vapour type (A-P)

## **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Physical state paste

Colour yellow

Odour No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : No data available

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 6.1 18.06.2025 4893032-00022 Date of first issue: 17.09.2019

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

### **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

## 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Skin contact exposure Ingestion

Eye contact

## Acute toxicity

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

#### Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Acute oral toxicity : LD50 (Rat): > 24.000 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 6.1 18.06.2025 4893032-00022 Date of first issue: 17.09.2019

LD50 (Mouse): > 24.000 mg/kg

LD50 (Dog): 2.000 mg/kg

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg

Target Organs: Central nervous system Symptoms: Vomiting, Dilatation of the pupil Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5,11 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

**Ethanol:** 

Acute oral toxicity : LD50 (Rat): 10.470 mg/kg

Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat, male): 116,9 mg/l

Exposure time: 4 h
Test atmosphere: vapour

Acute dermal toxicity : LD50 (Rabbit): > 15.800 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### **Components:**

Ivermectin:

Species : Rabbit

Result : No skin irritation

Ethanol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 6.1 18.06.2025 4893032-00022 Date of first issue: 17.09.2019

**Components:** 

Ivermectin:

Species : Rabbit

Result : Mild eye irritation

**Ethanol:** 

Species : Rabbit

Method : OECD Test Guideline 405

Result : Irritation to eyes, reversing within 21 days

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Components:** 

Ivermectin:

Exposure routes : Dermal Species : Humans

Result : Does not cause skin sensitisation.

**Ethanol:** 

Test Type : Mouse ear swelling test (MEST)

Exposure routes : Skin contact
Species : Mouse
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts

Result: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

Test Type: Mouse Lymphoma

Result: negative

**Ethanol:** 

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat

Application Route: Ingestion

Result: negative

### Carcinogenicity

Not classified based on available information.

#### **Components:**

#### Ivermectin:

Species : Rat Application Route : Oral

NOAEL : 1,5 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Species : Mouse Application Route : Oral

NOAEL : 2,0 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

## Reproductive toxicity

Not classified based on available information.

#### **Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Effects on foetal develop-

Test Type: Embryo-foetal development Species: Rat

ment

Application Route: Oral

Developmental Toxicity: NOAEL: 3.000 mg/kg body weight Result: No effects on fertility and early embryonic develop-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

ment were detected.

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 1.000 mg/kg body weight Result: No effects on fertility and early embryonic develop-

ment were detected.

Ivermectin:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0,6 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development

Species: Mouse

Application Route: Oral

Developmental Toxicity: NOAEL: 0,2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0,4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

Test Type: Development

Species: Rabbit Application Route: Oral

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

**Ethanol:** 

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Mouse

Application Route: Ingestion

Result: negative

STOT - single exposure

May cause damage to organs.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

#### **Components:**

Ivermectin:

Target Organs : Central nervous system Assessment : Causes damage to organs.

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### Components:

Ivermectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

### Repeated dose toxicity

#### **Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 30 mg/kg
Application Route : Ingestion
Exposure time : 3 d

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 600 mg/kg Application Route : Oral Exposure time : 19 d

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 600 mg/kg Application Route : Oral Exposure time : 30 d

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 600 mg/kg Application Route : Oral Exposure time : 90 d

Remarks : No significant adverse effects were reported

Ivermectin:

Species : Dog
NOAEL : 0,5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 6.1 18.06.2025 4893032-00022 Date of first issue: 17.09.2019

Exposure time : 14 Weeks

Target Organs : Central nervous system

Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1,2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Remarks : No significant adverse effects were reported

Species : Rat

NOAEL : 0,4 mg/kg

LOAEL : 0,8 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : spleen, Bone marrow, Kidney

**Ethanol:** 

Species : Rat

NOAEL : 1.730 mg/kg LOAEL : 3.200 mg/kg Application Route : Ingestion Exposure time : 90 Days

### **Aspiration toxicity**

Not classified based on available information.

### 11.2 Information on other hazards

#### **Endocrine disrupting properties**

Not classified based on available information.

**Product:** 

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

### **Experience with human exposure**

### **Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea,

Headache, Dizziness, Fever

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom-

iting, anorexia, Lack of coordination

### **SECTION 12: Ecological information**

#### 12.1 Toxicity

### **Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

**Ecotoxicology Assessment** 

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0,003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,0048 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0,000025 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9,1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

icity)

10.000

M-Factor (Chronic aquatic

toxicity)

10.000

**Ethanol:** 

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 14.200 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Ceriodaphnia dubia (water flea)): 5.012 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Chlorella vulgaris (Fresh water algae)): 275 mg/l

Exposure time: 72 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 6.1 18.06.2025 4893032-00022 Date of first issue: 17.09.2019

EC10 (Chlorella vulgaris (Fresh water algae)): 11,5 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50 (Protozoa): 5.800 mg/l

Exposure time: 4 h

Toxicity to fish (Chronic tox-

icity)

NOEC: >= 79 mg/l Exposure time: 100 d

Species: Oryzias latipes (Japanese medaka)

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 9,6 mg/l Exposure time: 9 d

Species: Daphnia magna (Water flea)

## 12.2 Persistence and degradability

#### **Components:**

Ivermectin:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 240 d

**Ethanol:** 

Biodegradability : Result: Readily biodegradable.

Biodegradation: 84 % Exposure time: 20 d

## 12.3 Bioaccumulative potential

#### **Components:**

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-

octanol/water

log Pow: 3,22

**Ethanol:** 

Partition coefficient: n-

octanol/water

log Pow: -0,35

### 12.4 Mobility in soil

#### **Components:**

**Ethanol:** 

Distribution among environmental compartments

log Koc: 0,2

### 12.5 Results of PBT and vPvB assessment

### **Product:**

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

### 12.6 Endocrine disrupting properties

### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

## 14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ivermectin)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ivermectin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 6.1 18.06.2025 4893032-00022 Date of first issue: 17.09.2019

(Ivermectin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Ivermectin)

IATA : Environmentally hazardous substance, solid, n.o.s.

(Ivermectin)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**ADR** 

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

**RID** 

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**IMDG** 

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen- : 956

ger aircraft)

Packing instruction (LQ) : Y956

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025 18.06.2025 4893032-00022 Date of first issue: 17.09.2019 6.1

Packing group

Labels Miscellaneous

14.5 Environmental hazards

Environmentally hazardous yes

Environmentally hazardous ves

Environmentally hazardous yes

**IMDG** 

Marine pollutant yes

IATA (Passenger)

Environmentally hazardous yes

IATA (Cargo)

Environmentally hazardous yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

## **SECTION 15: Regulatory information**

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation

Not applicable

Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

(Annex XIV)

Regulation (EU) No 2024/590 on substances that de: Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2

E1 ENVIRONMENTAL 100 t 200 t

**HAZARDS** 

#### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

#### The components of this product are reported in the following inventories:

DSL : not determined

AICS : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

**Full text of H-Statements** 

H225 : Highly flammable liquid and vapour.

H300 : Fatal if swallowed.

H311 : Toxic in contact with skin.
H319 : Causes serious eye irritation.

H370 : Causes damage to organs if swallowed.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Pyrantel Pamoate / Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation Flam. Liq. : Flammable liquids

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

**TWA** 

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention: PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sheet

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

#### Classification of the mixture:

#### Classification procedure:

STOT SE 2 H371 Calculation method
STOT RE 2 H373 Calculation method
Aquatic Acute 1 H400 Calculation method

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Pyrantel Pamoate / Ivermectin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 14.04.2025

 6.1
 18.06.2025
 4893032-00022
 Date of first issue: 17.09.2019

Aquatic Chronic 1 H410 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN